18 March 2020 | News
Advancing a domestic clinical trial of EC-18
Image credit- shuttershock.com
Enzychem Lifesciences, Corp., a global biopharmaceutical company headquartered in Seoul, Korea, is advancing a domestic clinical trial of EC-18, a new coronavirus treatment candidate, in South Korea. The company has also been in communication with the relevant U.S. government authorities for development collaboration.
EC-18 has high efficacy to reduce the gathering of inflammatory cells due to rapid removal of damage associated molecular pattern (DAMPs), that accumulate when cells are damaged by radiation and the compound also prevents tissue damage produced by the sudden activity inflammatory cells.
EC-18 is the company's proprietary compound originally derived from Sika deer antler, which acts as Pattern Recognition Receptors (PRR) (e.g., TLR4) endocytic trafficking accelerator contributing to swift removal of PAMPs/DAMPs. For acute respiratory distress syndrome associated with COVID-19, dysregulation of the TLRs signaling pathway is reported to be relevant.
With this unique mechanism of action, the company is developing EC-18 for indications including chemoradiation induced oral mucositis (CRIOM), chemotherapy induced neutropenia (CIN) and acute radiation syndrome (ARS).